Price
151.88
+0.31%52W Range
Market Cap
₹158.12 Cr
Traded: ₹0.36 Cr (0.23%) 0.0x
Free Float: ₹70.38 Cr (0.52% of FF traded)
Volume · 60D trend
23.56 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
42 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Profit | -- | -- | -- | -- | -2853.0% | -- |
| Return | +8.0% | +7.0% | -23.0% | -18.0% | -- | Stable |
| ROE | -- | +3.0% | -2.0% | -- | -- | Decelerating |
| Sales | -- | +19.0% | +3.0% | -- | +11.0% | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 49 | 58 | 38 | 46 | 45 | 45 | 44 | 41 | 39 | 40 | 40 | 38 | 38 | 38 | 46 | 45 |
| Expenses | 48 | 57 | 40 | 47 | 45 | 41 | 40 | 37 | 35 | 36 | 35 | 32 | 32 | 32 | 36 | 35 |
| Operating Profit | 1 | 1 | -2 | -1 | 0 | 4 | 4 | 5 | 4 | 4 | 5 | 5 | 6 | 6 | 10 | 10 |
| OPM % | 2.3% | 2.3% | -6.2% | -1.9% | 0.7% | 9.8% | 9.7% | 10.9% | 11.2% | 10.2% | 11.8% | 13.7% | 15.8% | 15.3% | 21.2% | 21.4% |
| Other Income | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest | 5 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit Before Tax | -6 | -5 | -9 | -8 | -6 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 7 | 7 |
| Tax % | -1.5% | -2.0% | -21.7% | -9.1% | -8.1% | 41.6% | 78.4% | 201.6% | 21.8% | 32.2% | 33.0% | 27.1% | 32.3% | 40.1% | 25.2% | 24.1% |
| Net Profit | -6 | -5 | -7 | -7 | -6 | 1 | 0 | -1 | 1 | 1 | 1 | 2 | 2 | 2 | 5 | 5 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | -3.8 | -3.3 | -4.8 | -6.8 | -5.4 | 0.3 | 0.1 | -0.6 | 0.6 | 1.0 | 1.3 | 1.7 | 2.0 | 1.9 | 5.7 | 5.7 |
| Sales Growth (YoY) | 7.8% | 30.0% | -13.9% | 11.1% | 15.4% | 11.8% | 9.6% | 9.9% | 3.9% | 6.9% | -12.1% | -16.7% | -14.7% | -- | -- | -- |
| Sales Growth (QoQ) | -- | 54.8% | -17.6% | 1.3% | 0.5% | 2.6% | 6.3% | 5.2% | -2.6% | 0.6% | 6.6% | -0.5% | 0.2% | -17.3% | 1.0% | -- |
| OP Growth (YoY) | 250.0% | -69.7% | -154.3% | -119.8% | -92.7% | 6.8% | -9.5% | -12.1% | -26.7% | -28.8% | -51.1% | -46.8% | -- | -- | -- | -- |
| OP Growth (QoQ) | -15.8% | 157.3% | -160.7% | -378.1% | -92.7% | 2.8% | -5.1% | 3.0% | 6.3% | -12.9% | -7.8% | -14.1% | 3.3% | -40.3% | 0.3% | -- |
| Profit Growth (YoY) | 28.7% | -1058.3% | -4581.8% | -1045.9% | -1030.0% | -62.9% | -90.9% | -139.1% | -67.0% | -45.8% | -77.0% | -70.7% | -65.1% | -65.0% | 28.0% | 104.0% |
| EPS Growth (YoY) | -- | -1048.6% | -4436.4% | -1026.7% | -943.8% | -66.3% | -91.5% | -135.7% | -67.3% | -46.4% | -77.0% | -70.7% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 30.4% | 29.4% | -25.2% | -1642.9% | 218.2% | 118.3% | -193.8% | -38.5% | -20.0% | -22.6% | -14.3% | 1.0% | -65.7% | -1.4% | -- |
| OP Margin | -- | 2.3% | -6.2% | -1.9% | 0.7% | 9.8% | 9.7% | 10.9% | 11.2% | 10.2% | 11.8% | 13.7% | 15.8% | 15.3% | 21.2% | 21.4% |
| Net Margin | -- | -8.5% | -18.9% | -15.3% | -12.3% | 1.2% | 0.3% | -1.5% | 1.5% | 2.4% | 3.0% | 4.2% | 4.8% | 4.8% | 11.5% | 11.8% |
| Material Cost % | -- | 61.0% | 50.0% | 53.0% | 52.0% | 51.0% | 51.0% | 48.0% | 51.0% | 52.0% | 53.0% | 50.0% | 48.0% | 47.0% | 47.0% | 44.0% |
| Employee Cost % | -- | 9.0% | 14.0% | 12.0% | 12.0% | 8.0% | 9.0% | 8.0% | 8.0% | 9.0% | 8.0% | 8.0% | 8.0% | 7.0% | 6.0% | 6.0% |
| P/S | 0.83 | 0.88 | 1.00 | 0.88 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 0.90 | 0.71 | 0.71 | 0.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Copy of Newspaper Publication (i.e., Dispatch of EGM Notice for the attention of the Equity shareholders)
Copy of Newspaper Advertisement, i.e Notice for attention of equity shareholders of the company.
Cut-off Date (Record Date) for Extraordinary General Meeting ("EGM") is fixed on September 2nd, 2026.
We are hereby submitting the Notice of the Extraordinary General Meeting (EGM) of the Company scheduled to be held on Wednesday, September 09, 2026 at 12:00 PM (IST) through Video Conference ....
This is to inform you that Mr. Pramod Kasat has tendered his resignation from the position of Independent Director of Natural Biogenex Private Limited ("Material Unlisted Subsidiary"), ....
Approved the Unaudited Consolidated & Standalone Financial Results of the Company for the Quarter ended June 30, 2026.
We hereby inform that the Unaudited Financial Results for the Quarter ended June 30, 2026, has been published in Business Line, an English Daily & Sanjevani a Kannada daily.
We are submitting herewith voting results & scrutinizers report of 33rd AGM of Natural Capsules Limited.
Please find enclosed herewith the copy of Press Release made to analysts and investors in connection with the Unaudited Consolidated & Standalone Financial Results for quarter ended June 30, 2026.
Please find enclosed herewith the copy of Investors Presentation in connection with the Unaudited Consolidated & Standalone Financial Results for quarter ended June 30, 2026.
Natural Biogenex Private Limited ("Material Unlisted Subsidiary"), at its Board Meeting held on today has appointed Mr. K. H. Honneshaiah as the new Chief Operating Officer of the Company.
1. Approved the unaudited Consolidated & Standalone Financial Results of the Company for the Quarter ended June 30, 2026. 2. Preferential Issue of Equity Shares and Warrants to Promoter.
33rd Annual General Meeting of the Company held on Wednesday August 12, 2026 at 12.10 P.M. through Video conferencing ("VC") other Audio-visual Means ("OAVM") and was concluded at 01:00 PM.
Natural Capsules Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Update on board meeting 1. ....
Natural Capsules Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve 1. To Consider and approve ....
Newspaper Publication for Completion of Dispatch of Notice of 33rd Annual General Meeting and Annual Report for F.Y 2025-26.
Annual Report for the Financial Year 2025-26.
Notice of the 33rd Annual General Meeting ("AGM") of the Company scheduled to be held on Wednesday, August 12, 2026, at 12:00 PM (IST) through Video Conference ("VC") or Other Audio Visual ....
The Record Date for 33rd Annual General Meeting is set on August 05, 2026; Wednesday.
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 - Copy of Newspaper Advertisement, i.e. Notice for attention of equity shareholders ....
Pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby submit the certificate received from Cameo Corporate Services Limited, Registrar & ....
This is to inform you that under Regulation 30(9) of SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015; Natural Biogenex Private Limited (" Material Unlisted Subsidiary"), ....
This is to inform you that under Regulation 30(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; Natural Biogenex Private Limited ("Material Unlisted Subsidiary"), ....
Notice to the shareholders for transfer of shares to Investor Education and Protection Fund (IEPF) has been published in Business Line; an English daily and Sanjevani a Kannada daily Newspapers.
Closure of Trading Window for dealing in the equity shares of the company shall remain closed for all Designated Person and their immediate relatives with effect from July 01, 2026, till ....
Pursuant to Regulation 30 and Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Audio recording of Conference Call held on Tuesday, ....
This has reference to our intimation under regulation 30(9) of SEBI (LODR) Regulation, 2015 submitted to the Stock Exchange on May 27, 2026, regarding the outcome of the Board Meeting of ....
Due to the Technical error in the previously published link for the Conference Call with the Investors/Analysts on the Stock Exchange, we are publishing the corrected link for the upcoming ....
We hereby inform that the audited financial results for the quarter and year ended March 31, 2026 has been published in Business Line, an english daily and Sanjevani, a Kannada daily.
Pursuant to Regulation 30 of SEBI (LODR) Reg. 2015, find enclosed herewith the copy of investor presentation in connection with the Audited Standalone & Consolidation Financial Results ....
Pursuant to Reg. 30 of SEBI (LODR) Reg 2015, Find enclosed herewith the copy of press release made to analysts and investors in connection with Audited Standalone & Consolidated Financial ....
We would like to inform you that the Company shall hold Conference Call with Investors on Tuesday, June 02, 2026 at 04:00 PM IST to discuss the Audited Financial Results for the Fourth ....
Pursuant to Regulation 24A of SEBI (LODR) Regulations, 2015. Please find enclosed the Annual Secretarial Compliance Report dated May 27, 2026 for the FY ended March 31, 2026 issued by Mr. ....
Natural Biogenex Private Limited (Material Subsidiary) at its BM held on May 27, 2026, has approved right issue of 11,11,200 equity shares of Rs. 10/-
Appointment of Mr. Akshay Dutta (M.No. A80481) as Company Secretary and Compliance Officer of the Company w.e.f. May 27, 2026.
Please find attached the Intimation of Allotment of 25,000 Equity Shares under ESOP.
1. Reappointment of Mr. Laxminarayana Moodra 2. Appointment of Mr. Akshay Dutta as Company Secretary and Compliance Officer 3. Appointment of Internal Auditor M/s Mallya & Mallya
Please find attached the Financial Results for FY ended on March 31, 2026
Approved the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026. Approved the re-appointment of Mr. Shri Laxminarayana Moondra ....
Natural Capsules Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve Dear Sir/Madam, Pursuant ....
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Resignation of Company Secretary & Compliance Officer
Please find enclosed newspaper publication regarding second 100 days campaign-" Saksham Niveshak"
Please find attached the intimation for Second 100 Days Campaign - Saksham Niveshak.
Please find attached the certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018.
Please find enclosed copies of newspapers
Please find attached Scrutinizer''s Report.
Voting Results of Postal Ballot Notice
Intimation of Closure of Trading Window
Annual Reports
15Credit Ratings
6Concalls
19Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Jun 2025
30 Jun 2025Jun 2025
30 Jun 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023Jun 2023
30 Jun 2023Feb 2023
28 Feb 2023Oct 2022
31 Oct 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021